Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus
In February 1994, a clinical trial by the Pediatrics AIDS Clinical Trials Group (PACTG 076) demonstrated, for the first time, that it was possible to reduce the risk of vertical transmission of human immunodeficiency virus type 1 (HIV-1) by nearly 70% by means of a triple therapeutic regimen: 1) ora...
Published in: | Revista Panamericana de Salud Pública |
---|---|
Format: | Article in Journal/Newspaper |
Language: | English Spanish Portuguese |
Published: |
Pan American Health Organization
2001
|
Subjects: | |
Online Access: | https://doi.org/10.1590/s1020-49892001000500020 https://doaj.org/article/610be13d6e044452ad270b01b6fdfc1f |
id |
ftdoajarticles:oai:doaj.org/article:610be13d6e044452ad270b01b6fdfc1f |
---|---|
record_format |
openpolar |
spelling |
ftdoajarticles:oai:doaj.org/article:610be13d6e044452ad270b01b6fdfc1f 2023-05-15T15:12:41+02:00 Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus 2001-05-01T00:00:00Z https://doi.org/10.1590/s1020-49892001000500020 https://doaj.org/article/610be13d6e044452ad270b01b6fdfc1f EN ES PT eng spa por Pan American Health Organization http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500020&lng=en&tlng=en https://doaj.org/toc/1020-4989 1020-4989 doi:10.1590/s1020-49892001000500020 https://doaj.org/article/610be13d6e044452ad270b01b6fdfc1f Revista Panamericana de Salud Pública, Vol 9, Iss 5, Pp 345-354 (2001) VIH-1 transmisión perinatal antirretrovíricos prevención cesárea Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 article 2001 ftdoajarticles https://doi.org/10.1590/s1020-49892001000500020 2022-12-31T11:39:02Z In February 1994, a clinical trial by the Pediatrics AIDS Clinical Trials Group (PACTG 076) demonstrated, for the first time, that it was possible to reduce the risk of vertical transmission of human immunodeficiency virus type 1 (HIV-1) by nearly 70% by means of a triple therapeutic regimen: 1) oral zidovudine (ZDV) beginning anytime between the 14th and 34th week of gestation until the end of pregnancy; 2) intravenous ZDV during pregnancy, and 3) administration of oral ZDV to neonates during the first 6 weeks of life. Later, epidemiologic studies performed in the United States of America and France showed that this regimen drastically reduced perinatal transmission in clinical practice. Since then, important strides have been made, not only in terms of treatment (new drugs and highly effective therapeutic regimens) and diagnosis (tests that can measure the viral load), but also in terms of an increased understanding of the pathogenesis of perinatal transmission of HIV-1. This report contains: a) a review of special considerations to be kept in mind when administering antiretroviral agents to pregnant women; b) a current overview of the results of clinical and epidemiologic trials dealing with the prevention of perinatal transmission of HIV-1; c) a look at the use of tests for measuring HIV-1 RNA (viral load) during pregnancy; d) the most recent recommendations on the use of antiretroviral chemoprophylaxis and elective cesarean section for reducing perinatal viral transmission. These recommendations apply to the United States, and other countries may prefer to use different approaches. Article in Journal/Newspaper Arctic Directory of Open Access Journals: DOAJ Articles Arctic Revista Panamericana de Salud Pública 9 5 345 354 |
institution |
Open Polar |
collection |
Directory of Open Access Journals: DOAJ Articles |
op_collection_id |
ftdoajarticles |
language |
English Spanish Portuguese |
topic |
VIH-1 transmisión perinatal antirretrovíricos prevención cesárea Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
spellingShingle |
VIH-1 transmisión perinatal antirretrovíricos prevención cesárea Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus |
topic_facet |
VIH-1 transmisión perinatal antirretrovíricos prevención cesárea Medicine R Arctic medicine. Tropical medicine RC955-962 Public aspects of medicine RA1-1270 |
description |
In February 1994, a clinical trial by the Pediatrics AIDS Clinical Trials Group (PACTG 076) demonstrated, for the first time, that it was possible to reduce the risk of vertical transmission of human immunodeficiency virus type 1 (HIV-1) by nearly 70% by means of a triple therapeutic regimen: 1) oral zidovudine (ZDV) beginning anytime between the 14th and 34th week of gestation until the end of pregnancy; 2) intravenous ZDV during pregnancy, and 3) administration of oral ZDV to neonates during the first 6 weeks of life. Later, epidemiologic studies performed in the United States of America and France showed that this regimen drastically reduced perinatal transmission in clinical practice. Since then, important strides have been made, not only in terms of treatment (new drugs and highly effective therapeutic regimens) and diagnosis (tests that can measure the viral load), but also in terms of an increased understanding of the pathogenesis of perinatal transmission of HIV-1. This report contains: a) a review of special considerations to be kept in mind when administering antiretroviral agents to pregnant women; b) a current overview of the results of clinical and epidemiologic trials dealing with the prevention of perinatal transmission of HIV-1; c) a look at the use of tests for measuring HIV-1 RNA (viral load) during pregnancy; d) the most recent recommendations on the use of antiretroviral chemoprophylaxis and elective cesarean section for reducing perinatal viral transmission. These recommendations apply to the United States, and other countries may prefer to use different approaches. |
format |
Article in Journal/Newspaper |
title |
Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus |
title_short |
Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus |
title_full |
Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus |
title_fullStr |
Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus |
title_full_unstemmed |
Uso recomendado de antirretrovíricos en embarazadas infectadas por el VIH-1 para reducir la transmisión perinatal del virus |
title_sort |
uso recomendado de antirretrovíricos en embarazadas infectadas por el vih-1 para reducir la transmisión perinatal del virus |
publisher |
Pan American Health Organization |
publishDate |
2001 |
url |
https://doi.org/10.1590/s1020-49892001000500020 https://doaj.org/article/610be13d6e044452ad270b01b6fdfc1f |
geographic |
Arctic |
geographic_facet |
Arctic |
genre |
Arctic |
genre_facet |
Arctic |
op_source |
Revista Panamericana de Salud Pública, Vol 9, Iss 5, Pp 345-354 (2001) |
op_relation |
http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000500020&lng=en&tlng=en https://doaj.org/toc/1020-4989 1020-4989 doi:10.1590/s1020-49892001000500020 https://doaj.org/article/610be13d6e044452ad270b01b6fdfc1f |
op_doi |
https://doi.org/10.1590/s1020-49892001000500020 |
container_title |
Revista Panamericana de Salud Pública |
container_volume |
9 |
container_issue |
5 |
container_start_page |
345 |
op_container_end_page |
354 |
_version_ |
1766343342743879680 |